GH Research (GHRS) Enterprise Value (2020 - 2025)
GH Research (GHRS) recorded quarterly Enterprise Value of -$100.8 million in Q4 2025, little changed quarter-over-quarter from -$100.8 million in Q3 2025, and up 16.13% on a YoY basis from -$86.8 million in Q4 2024.
GH Research (GHRS) Enterprise Value (2020 - 2025) Analysis & Trends
GH Research's Enterprise Value history runs 6 years deep, the most recent figure standing at -$100.8 million for Q4 2025.
- In Q4 2025, Enterprise Value rose 16.13% year-over-year to -$100.8 million; the TTM figure through Dec 2025 stood at -$100.8 million (up 16.13% YoY), while the FY2025 annual figure was -$100.8 million, up 16.13% from the prior year.
- Enterprise Value was -$100.8 million for Q4 2025 at GH Research, roughly flat from -$100.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$5.9 million in Q1 2021 to a low of -$280.7 million in Q3 2021.
- Historically, Enterprise Value has averaged -$163.3 million across 5 years, with a median of -$131.6 million in 2023.
- The sharpest annual moves came in 2021 and 2024: Enterprise Value slumped 5535620.0% in 2021, then jumped 44.65% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$276.8 million in 2021, then surged by 40.04% to -$166.0 million in 2022, then rose by 19.23% to -$134.0 million in 2023, then rose by 10.34% to -$120.2 million in 2024, then rose by 16.13% to -$100.8 million in 2025.
- The last three Enterprise Value figures came in at -$100.8 million (Q4 2025), -$100.8 million (Q3 2025), and -$100.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -584.73 Mn |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | -100.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -100.79 Mn |
| Sep 30, 2025 | -100.79 Mn |
| Jun 30, 2025 | -100.79 Mn |
| Mar 31, 2025 | -113.35 Mn |
| Dec 31, 2024 | -120.18 Mn |
| Sep 30, 2024 | -122.58 Mn |
| Jun 30, 2024 | -129.10 Mn |
| Mar 31, 2024 | -128.83 Mn |
| Dec 31, 2023 | -134.04 Mn |
| Sep 30, 2023 | -221.45 Mn |
| Jun 30, 2023 | -220.68 Mn |
| Mar 31, 2023 | -220.01 Mn |
| Dec 31, 2022 | -165.96 Mn |
| Sep 30, 2022 | -276.78 Mn |
| Jun 30, 2022 | -265.38 Mn |
| Mar 31, 2022 | -276.78 Mn |
| Dec 31, 2021 | -276.79 Mn |
| Sep 30, 2021 | -280.75 Mn |
| Jun 30, 2021 | -5.90 Mn |
| Mar 31, 2021 | -5.90 Mn |